Get startedLog in
    Picture of Novo Nordisk A/S logo

    NVO — Novo Nordisk A/S News Story

    0.000.00%
    us flag iconLast trade - 00:00
    HealthcareAdventurousLarge CapSuper Stock
    All News

    Brief: Novo Nordisk CagriSema Reduced Food Noise, Brain Response to High-Calorie Foods in Obesity Study

    Picture of Novo Nordisk A/S logoNovo Nordisk A/S
    30/09/2026 13:30
    BRIEF-Novo Nordisk CagriSema Reduced Food Noise, Brain Response to High-Calorie Foods in Obesity Study
    Sept 30 (Reuters) - Novo Nordisk A/S NOVOb.CO:
    • NOVO NORDISK: CAGRISEMA 2.4MG/2.4MG REDUCED ABDOMINAL & ORGAN FAT VERSUS PLACEBO, ACHIEVED 14.3% WEIGHT LOSS AT WEEK 40 IN DIABETES MRI SUB-STUDY
    • NOVO NORDISK: CAGRISEMA 2.4MG/2.4MG MAINTAINED BONE HEALTH WITH 14.2% BODY-WEIGHT REDUCTION AT WEEK 68 IN TYPE 2 DIABETES TRIAL
    • NOVO NORDISK: CAGRISEMA ACHIEVED 22.4% BODY WEIGHT REDUCTION VERSUS PLACEBO AT 52 WEEKS IN FUNCTIONAL MAGNETIC RESONANCE IMAGING STUDY
    • NOVO NORDISK: CAGRISEMA REDUCED 'FOOD NOISE' AND MODIFIED BRAIN RESPONSE TO HIGH-CALORIE FOODS IN OBESITY STUDY

    Further company coverage: [NOVOb.CO]

     ((Reuters.Briefs@thomsonreuters.com;))

    Recent news on Novo Nordisk A/S

    See all news